{"id":"W4311734051","doi":"10.1097/ccm.0000000000005716","title":"Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial*","year":2022,"lang":"en","type":"article","venue":"Critical Care Medicine","topic":"IL-33, ST2, and ILC Pathways","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Discovery Centre","funders":"","keywords":"Medicine; ARDS; Clinical endpoint; Pneumonia; Placebo; Randomized controlled trial; Internal medicine; Adverse effect; Cytokine release syndrome; Hazard ratio; Immunology; Lung; Coronavirus disease 2019 (COVID-19); Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001746085,0.001817658,0.003000338,0.0003595976,0.0003380215,0.00106563,0.0006996325,0.001868062,0.005172035],"category_scores_gemma":[0.001513268,0.0006315407,0.002033832,0.0004078872,0.0008078864,0.001034248,0.0003398128,0.002197616,0.0006982294],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006929517,"about_ca_system_score_gemma":0.001297399,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006907073,"about_ca_topic_score_gemma":0.001639146,"domain_scores_codex":[0.9994329,0.0003114247,0.00003804537,0.0000881084,0.0000393495,0.00009020748],"domain_scores_gemma":[0.9994056,0.0001776124,0.0001392328,0.00004085619,0.00005264397,0.0001839642],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9808904,0.003452074,0.0005246671,0.0006212834,0.0007610806,0.00003654505,0.00002441764,0.0002470022,0.001820572,0.00008261467,0.0007574644,0.01078174],"study_design_scores_gemma":[0.9764239,0.0218525,0.000657492,0.00002170019,0.0002562074,0.00001700126,0.000007782022,0.000172533,0.0001261659,0.00006173745,0.0003970372,0.00000600343],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9656282,0.01602171,0.001100384,0.001868588,0.001244124,0.009003261,0.001992876,0.0001569598,0.002983911],"genre_scores_gemma":[0.9709677,0.007420017,0.00232667,0.002429336,0.0009704129,0.01049377,0.001878915,0.00002950535,0.003483709],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005172035,"threshold_uncertainty_score":0.01730222,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02216302880472214,"score_gpt":0.3117859823458574,"score_spread":0.2896229535411353,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}